Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients

被引:500
作者
Targher, G. [1 ,2 ]
Bertolini, L. [2 ]
Rodella, S. [3 ]
Zoppini, G. [1 ]
Lippi, G. [4 ]
Day, C. [5 ]
Muggeo, M. [1 ]
机构
[1] Univ Verona, Osped Civile Maggiore, Dept Biomed & Surg Sci, Div Endocrinol, I-37126 Verona, Italy
[2] Sacro Cuore Hosp, Dept Internal Med, Negrar, VR, Italy
[3] Sacro Cuore Hosp, Dept Radiol, Negrar, VR, Italy
[4] Univ Verona, Dept Biomed & Morphol Sci, Sect Clin Chem, I-37100 Verona, Italy
[5] Univ Newcastle, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England
关键词
chronic kidney disease; CKD; liver disease; liver fat; metabolic syndrome; microvascular complications; NAFLD; non-alcoholic fatty liver disease; retinopathy; type; 2; diabetes;
D O I
10.1007/s00125-007-0897-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims/hypothesis Non-alcoholic fatty liver disease (NAFLD) is associated with an increased risk of cardiovascular disease in type 2 diabetes. Currently, there is a lack of information on associations between NAFLD and microvascular complications of diabetes. We assessed the associations between NAFLD and both chronic kidney disease (CKD) and retinopathy in a large cohort of type 2 diabetic individuals using a cross-sectional design. Methods Prevalence rates of retinopathy (by ophthalmoscopy) and CKD (defined as overt proteinuria and/or estimated GFR <= 60 ml min(-1) 1.73 m(-2)) were assessed in 2,103 type 2 diabetic individuals who were free of diagnosed cardiovascular disease and viral hepatitis. NAFLD was ascertained by patient history, blood sampling and liver ultrasound. Results NAFLD patients had higher (p < 0.001) age- and sex-adjusted prevalence rates of both non-proliferative (39 vs 34%) and proliferative/laser-treated retinopathy (11 vs 5%), and CKD (15 vs 9%) than counterparts without NAFLD. In logistic regression analysis, NAFLD was associated with increased rates of CKD (odds ratio 1.87; 95% CI 1.3-4.1, p = 0.020) and proliferative/laser-treated retinopathy (odds ratio 1.75; 1.1-3.7, p = 0.031) independently of age, sex, BMI, waist circumference, hypertension, diabetes duration, HbA(1c), lipids, smoking status and medications use. Conclusions/interpretation Our findings suggest that NAFLD is associated with an increased prevalence of CKD and proliferative/laser-treated retinopathy in type 2 diabetic individuals independently of numerous baseline confounding factors. Further studies are required to confirm the reproducibility of these results and to evaluate whether NAFLD contributes to the development or progression of CKD and retinopathy.
引用
收藏
页码:444 / 450
页数:7
相关论文
共 36 条
  • [1] Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis
    Abiru, S
    Migita, K
    Maeda, Y
    Daikoku, M
    Ito, M
    Ohata, K
    Nagaoka, S
    Matsumoto, T
    Takil, Y
    Kusumoto, K
    Nakamura, M
    Komori, A
    Yano, K
    Yatsuhashi, H
    Eguchi, K
    Ishibashi, H
    [J]. LIVER INTERNATIONAL, 2006, 26 (01) : 39 - 45
  • [2] Nonalcoholic fatty liver disease
    Adams, LA
    Angulo, P
    Lindor, KD
    [J]. CANADIAN MEDICAL ASSOCIATION JOURNAL, 2005, 172 (07) : 899 - 905
  • [3] Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis
    Albano, E
    Mottaran, E
    Vidali, M
    Reale, E
    Saksena, S
    Occhino, G
    Burt, AD
    Day, CP
    [J]. GUT, 2005, 54 (07) : 987 - 993
  • [4] Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation
    Alessi, MC
    Bastelica, D
    Mavri, A
    Morange, P
    Berthet, B
    Grino, M
    Juhan-Vague, I
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2003, 23 (07) : 1262 - 1268
  • [5] [Anonymous], 2007, DIABETES CARE, DOI DOI 10.2337/DC07-S004
  • [6] Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos Nutrition and Liver Study
    Bedogni, G
    Miglioli, L
    Masutti, F
    Tiribelli, C
    Marchesini, G
    Bellentani, S
    [J]. HEPATOLOGY, 2005, 42 (01) : 44 - 52
  • [7] A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
    Belfort, Renata
    Harrison, Stephen A.
    Brown, Kenneth
    Darland, Celia
    Finch, Joan
    Hardies, Jean
    Balas, Bogdan
    Gastaldelli, Amalia
    Tio, Fermin
    Pulcini, Joseph
    Berria, Rachele
    Ma, Jennie Z.
    Dwivedi, Sunil
    Havranek, Russell
    Fincke, Chris
    DeFronzo, Ralph
    Bannayan, George A.
    Schenker, Steven
    Cusi, Kenneth
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (22) : 2297 - 2307
  • [8] Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity
    Browning, JD
    Szczepaniak, LS
    Dobbins, R
    Nuremberg, P
    Horton, JD
    Cohen, JC
    Grundy, SM
    Hobbs, HH
    [J]. HEPATOLOGY, 2004, 40 (06) : 1387 - 1395
  • [9] The pathobiology of diabetic complications - A unifying mechanism
    Brownlee, M
    [J]. DIABETES, 2005, 54 (06) : 1615 - 1625
  • [10] Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis
    Chalasani, N
    Deeg, MA
    Crabb, DW
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (08) : 1497 - 1502